Dutch Life Sciences Trend Analysis 2017

THE LATEST FIGURES ON THE DUTCH LIFE SCIENCES & BIOTECHNOLOGY INDUSTRY BROUGHT TO YOU BY C5 COMMUNICATIONS AND BIOTECHGATE





Dutch Life Sciences Trend Analysis 2017

SOURCE: biotechgate.com

The "Dutch Life Sciences Trend Analysis" is based on data entered in the Biotechgate Database available at www.biotechgate.com.

The statistics and graphs in this presentation are based on figures and information entered in this database and we do not guarantee any accuracy hereof.

The Netherlands is a leader in the life sciences and biotech industry, ranked as **No.4 worldwide for medical technology patent applications** and **No. 9 worldwide for biotechnology patent applications.**

More than **2,500 life sciences, medical technology companies and research organisations** call the country home, and the region has attracted major multinational companies, including **Johnson & Johnson**, **GlaxoSmithKline**, **Amgen and Medtronic**, as a hub for manufacturing, R&D and logistics.

With the majority of innovative life sciences companies clustered within a 120-mile radius, **collaboration** is a key focus.

In 2016, the two largest public-private institutes in the life sciences and health sector, the Centre for Translational Molecular Medicine and the Top Institute Pharma, came together to form Lygature.

This independent third party was created to help **preserve Dutch R&D expertise and support new initiatives**, driving the development of innovative medical solutions.

R&D is also a core focus, receiving an estimated 2 Billion Euros in investment each year.

This has undoubtedly contributed to the global success of Dutch life sciences, such as the **Leiden Bio Science Park**, which has consistently ranked in the **top five most successful science parks in Europe**.

The Park houses **93 dedicated medical life sciences companies** and institutions, internationally acclaimed research institutes and the largest number of bioscience start-ups in Holland.





Dutch Life Sciences Trend Analysis 2017

Content
Overview of the Dutch Industry
Life Sciences & Biotechnology Industry - Overview
Life Sciences & Biotechnology Industry - Number of Employees
Life Sciences & Biotechnology Industry - Company Ownership
Biotech Companies - Foundation Timeline
Biotechnology Companies -Key Activities
Biotech products - Pipeline
Biotech products - Breakdown by Indication
Biotechnology Financing in the Netherlands – 5 year report
Major Biotech Venture Financing Rounds in 2016
Supports





Overview

Life Science Industry

2017 Statistics	
Total Biotech companies	462
Medtech companies	122
Investor Companies	29
Health Tech	39
Public/Non-Profit/Medical Facilities	181
Other life sciences related companies	877
Percentage of publicly owned companies	1.8%
Life Sciences Venture Financing 2015/2016	USD 150.8m/
	140.2m
Number of Technologies	162
Licensing Opportunities	110

Biotechnology Industry


2017 Statistics	
Total Biotech companies	462
Biotech – Therapeutics	103
Biotech – R&D Services	231
Biotech – Other	128
Percentage of SMEs	87%
Percentage of publicly owner companies	1.8%
Biotech Venture Financing 2015/2016	USD 124.8m /
	71.2m
Licensing opportunities	96






Number of Employees

LIFE SCIENCES



BIOTECH









Company Ownership

LIFE SCIENCES




BIOTECH








Biotech Companies - Foundation Timeline







Biotechnology Companies - Key Activities








Biotech products - Pipeline


NUMBER OF BIOTECH PRODUCTS IN DEVELOPMENT








Breakdown of Biotech Products



Biotechnology Financing – 5 year report







Discover The Latest European Developments In Life Sciences IP

On the 11th and 12th of October, C5 will be hosting the Life Sciences IP Summit in Munich, Germany.

Join us for the fourth year of this leading conference to discover:

- Pharmaceutical lifecycle management strategies
- How to protect your patent portfolio using Preliminary Injunctions
- Best practices for effective Cross Border Litigation
- How to navigate the CRISPR patent landscape ...and many more exciting topics delivered by industry experts





Join us to gain practical insights from industry experts on how to maximise the value of your Pharma and Biotech IP, manage changing regulations and innovate in new markets!

Download the DRAFT AGENDA by clicking here!

Book your place TODAY at the cheapest price!